Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Original publication

DOI

10.1016/S0140-6736(14)60226-9

Type

Journal article

Journal

Lancet

Publication Date

29/03/2014

Volume

383

Pages

1103 - 1104

Keywords

Cost-Benefit Analysis, Humans, Immunization Programs, Infant, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, United Kingdom